SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $32
SVB Leerink analyst Mani Foroohar maintains AlloVir (NASDAQ:ALVR) with a Outperform and lowers the price target from $37 to $32.
AlloVir Saturday Announced Prelim. Data From Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study At American Society Of Hematology Meeting
Of the 23 high-risk allogeneic hematopoietic cell transplant patients in this analysis, no end-organ viral disease was observed
Of the 13 patients who completed through the Week 14 primary endpoint, 11 remained free of
SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $37
SVB Leerink analyst Mani Foroohar maintains AlloVir (NASDAQ:ALVR) with a Outperform and lowers the price target from $41 to $37.
AlloVir Q3 EPS $(0.72) Down From $(0.58) YoY
AlloVir (NASDAQ:ALVR) reported quarterly losses of $(0.72) per share. This is a 24.14 percent decrease over losses of $(0.58) per share from the same period last year.
Morgan Stanley Maintains Overweight on AlloVir, Raises Price Target to $48
Morgan Stanley analyst Matthew Harrison maintains AlloVir (NASDAQ:ALVR) with a Overweight and raises the price target from $47 to $48.
44 Biggest Movers From Yesterday
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.
AlloVir Earlier Granted FDA Orpha Drug Status For ‘Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpes virus-6, Epstein Barr virus, and adenovirus’
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=747920
Morgan Stanley Maintains Overweight on AlloVir, Raises Price Target to $225
Morgan Stanley maintains AlloVir (NASDAQ:ALVR) with a Overweight and raises the price target from $175 to $225.